Business
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Robert P. Edwards, MD, McCall Chair of Obstetrics, Gynecology, and Reproductive Science at the University of Pittsburgh School of Medicine Robert P. Edwards, MD, McCall Chair of Obstetrics, Gynecology, and Reproductive Science at the University of Pittsburgh School of Medicine OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:
About this update from Aim Immunotech Inc.
[{"type":"image","alt":"AIM ImmunoTech Inc.","displaySize":"","headline":null,"caption":"AIM ImmunoTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KYO5lLNJMwtczbtJGn_KoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNA--/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/KYO5lLNJMwtczbtJGn_KoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNA--/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160}},"lazy":false},{"type":"text","content":"Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin","length":139,"tagName":"p"},{"type":"text","content":"Robert P. Edwards, MD, McCall Chair of Obstetrics, Gynecology, and Reproductive Science at the University of Pittsburgh School of Medicine","length":138,"tagName":"p"},{"type":"image","alt":"Robert P. Edwards, MD, McCall Chair of Obstetrics, Gynecology, and Reproductive Science at the University of Pittsburgh School of Medicine","displaySize":"","headline":null,"caption":"Robert P. Edwards, MD, McCall Chair of Obstetrics, Gynecology, and Reproductive Science at the University of Pittsburgh School of Medicine","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":2376,"height":2970,"url":"https://media.zenfs.com/en/globenewswire.com/931d901bc3fd4f2ec1d85f4b91b6b210"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vsUXGHGvesrPvpVGiN9_Lg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEyMDA-/https://media.zenfs.com/en/globenewswire.com/931d901bc3fd4f2ec1d85f4b91b6b210","width":960,"height":1200},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0WNx30Rq3Zhp3jJyXjTOgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTgwMA--/https://media.zenfs.com/en/globenewswire.com/931d901bc3fd4f2ec1d85f4b91b6b210","width":640,"height":800},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/m4.bWSu07Cmyzs1T3ulzbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMDAw/https://media.zenfs.com/en/globenewswire.com/931d901bc3fd4f2ec1d85f4b91b6b210","width":1200,"height":1500}}},{"type":"text","content":"OCA...